We are a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates that utilize the body's natural nutrient transporter mechanisms to improve the therapeutic benefits of drugs.
This icon indicates a link to an external site.
Thu, 04 Feb 2010
XenoPort Announces Horizant(TM) as Brand Name for XP13512
Fri, 08 Jan 2010
XenoPort to Present at the 28th Annual J.P.
Morgan Healthcare Conference
November 19, 2009
Astellas and XenoPort Announce Submission of a New Drug Application in Japan
Requesting PMDA Approval of ASP8825/XP13512 for Restless Legs Syndrome
Thursday, January 14, 2010 9:00 a.m. PST
XenoPort, Inc. at 28th Annual J.P. Morgan Healthcare Conference
Tuesday, November 03, 2009 4:30 p.m. ET
Q3 2009 XenoPort, Inc. Earnings Conference Call
Legal Message | Privacy | © 2008. All rights reserved.